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The intracellular signaling molecule TRAF6 is critical
for Toll-like receptor (TLR)-mediated activation of
dendritic cells (DCs). We now report that DC-specific
deletion of TRAF6 (TRAF6DDC) resulted, unexpect-
edly, in loss of mucosal tolerance, characterized by
spontaneous development of T helper 2 (Th2) cells
in the lamina propria and eosinophilic enteritis and
fibrosis in the small intestine. Loss of tolerance
required the presence of gut commensal microbiota
but was independent of DC-expressed MyD88.
Further, TRAF6DDC mice exhibited decreased regu-
latory T (Treg) cell numbers in the small intestine and
diminished induction of iTreg cells in response to
model antigen. Evidence suggested that this defect
was associated with diminished DC expression
of interleukin-2 (IL-2). Finally, we demonstrate
that aberrant Th2 cell-associated responses in
TRAF6DDC mice could be mitigated via restoration
of Treg cell activity. Collectively, our findings reveal
a role for TRAF6 in directing DC maintenance of in-
testinal immune tolerance through balanced induc-
tion of Treg versus Th2 cell immunity.
INTRODUCTION
Microbial pathogens have long been understood to produce in-
flammatory stimuli essential to induction of adaptive immune re-
sponses, and there is now increasing interest in understanding
the relationship between microbiota and maintenance of im-
mune cell tolerance (Maloy and Powrie, 2011; Swiatczak andRe-
scigno, 2012). Pathogen-associated molecular patterns
(PAMPs) derived from pathogenic, as well as commensal, micro-
biota are recognized by Toll-like receptors (TLRs) that are highlyexpressed by dendritic cells (DCs) along the mucosal lining
(Maloy and Powrie, 2011; Pulendran et al., 2010). DCs are
specialized antigen-presenting cells (APCs) that are capable, un-
der inflammatory conditions, of providing costimulatory signals
and efficient antigen presentation through major histocompati-
bility complex (MHC) to T cells (Steinman, 2012). These functions
are critical for an effective adaptive immune response, but DCs
are now also recognized as key cellular keepers of immune toler-
ance (Manicassamy and Pulendran, 2011; Rescigno, 2010).
What remains unclear is the degree to which this dual role is
balanced by dispatchment of specialized subsets of DCs versus
specific tuning of DC-intrinsic signaling mechanisms to affect
certain immunologic outcomes. Past attempts to address these
issues via ex vivo analyses of DC phenotypes have often been
hampered by the keen sensitivity of DCs to external manipula-
tion. The recent development of a transgenic mouse model
enabling specific genetic targeting to the DC compartment
represents amajor step forward in conducting physiologic in vivo
analysis of DC function (Caton et al., 2007).
The molecular adaptor protein TRAF6 integrates upstream
signals from both MyD88-dependent IL-1R-TLR superfamily
pathways, as well as some tumor necrosis factor receptor
(TNFR) superfamily members, including CD40 and RANK (Inoue
et al., 2007; Walsh et al., 2006). Activation of TRAF6, a noncon-
ventional RING finger E3 ligase, which catalyzes formation of
K63-linked ubiquitin chains, results in downstream activation of
the NF-kB, MAPK, and PI3K pathways (Deng et al., 2000; Inoue
et al., 2007). Activation of TRAF6-dependent signaling is associ-
ated with induction of inflammatory gene expression products,
including IL-6 and IL-12. We have previously shown that DCs
derived from TRAF6-deficient (Traf6/) mice or Traf6/ fetal
liver cell chimeras exhibit substantial defects in maturation and
inflammatory cytokine elaboration in response to IL-1R-TLR su-
perfamily ligands and TNF superfamily members, and that
Traf6/ DCs adoptively transferred into third party hosts
possess decreased capability to induce antigen-dependent
T cell expansion and interferon-g (IFN-g) induction (Kobayashi
et al., 2003). However, because Traf6/ mice die perinatallyImmunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc. 1211
Figure 1. Generation of Mice Lacking TRAF6 Specifically in the DC Compartment
(A) Quantitative PCR of the floxed region of the Traf6 gene was performed with genomic DNA from TRAF6DDC (TRAF6f/f-CD11cCre) and control (TRAF6f/f)
FACS-sorted cells to measure degree of deletion in various cell types. A sequence from the TRANCE (Tnfsf11) gene was used as a control for sample stan-
dardization. (*, deletion not detected).
(B) IL-12 expression in wild-type (WT) or TRAF6DDC (DDC) mice after intravenous injection with PBS, LPS, or CpG. IL-12p40/p70 was detected by intracellular
staining for splenocytes isolated at 2 hr after injection. The representative FACS plots were gated on CD11chiMHC class IIhi DCs.
(C and D) IL-12p40 mRNA production after in vitro stimulation of MACS-sorted splenic DCs with LPS or CpG. (C) IL-12p40 expression was determined by qPCR
from mRNA 1 hr after stimulation. (D) IL-12p40 from culture medium was measured by ELISA 12 hr after stimulation.
(E) Intracellular IFN-g level was determined from splenocytes 7 days after infection with LCMV. Shown are representative FACS plots gated on CD4+ T cells.
The histograms in (C) and (D) represent mean ± SD. FACS plots in (B) and (E) are representative of at least three separate experiments.
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chimeras develop progressive inflammatory disease character-
ized by massive organ infiltration of Th2-like cells (Chiffoleau
et al., 2003), it has not been possible to specifically examine
the in situ role of DC-expressed TRAF6 in the context of physio-
logic immune responses or immune homeostasis.
Therefore, we have generatedmice lacking TRAF6 specifically
in the DC compartment (TRAF6DDC.) We report here that
despite defective activation of TRAF6-deficient DCs in peripheral
lymphoid organs like the spleen, we have made the striking
observation that TRAF6DDC mice develop spontaneous loss of
immune tolerance in the gut that is associated with both
decreased Treg cell numbers and the presence of microbiota.
These findings highlight a unique role for TRAF6 in DC function
and serve to elucidate the relationship between microbiota and
DCs in the maintenance of immune tolerance.
RESULTS
Generation ofMice Lacking TRAF6Specifically in theDC
Compartment
To generate TRAF6DDC mice lacking TRAF6 specifically in the
DC compartment, we have crossed mice carrying a floxed
Traf6 exon 1 allele (which we have previously described; King
et al., 2006) with CD11c-Cre (Itgax-Cre) transgenic mice (Caton
et al., 2007). DCs sorted from spleens of TRAF6DDCmice exhibit
specific deletion of TRAF6 compared to other sorted cell types
as determined by qPCR of genomic DNA samples (Figure 1A).
Specific deletion was further observed in DCs isolated from
other tissues as well (data not shown.) To determine whether1212 Immunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc.splenic DCs from TRAF6DDC mice exhibit predicted defective
responses to inflammatory stimuli, we measured IL-12 expres-
sion in response to both in vivo (Figure 1B) and in vitro (Figures
1C and 1D) treatment with the TLR ligands LPS and CpG DNA
and revealed that cytokine production is reduced in the absence
of TRAF6. To demonstrate the effect of DC-specific TRAF6 defi-
ciency on T cell activation under inflammatory conditions in vivo,
we infected TRAF6DDC mice with LCMV and splenic CD4+
T cells were assayed for CD44 upregulation and IFN-g produc-
tion 7 days later, revealing a severely reduced IFN-g+ cell popu-
lation in TRAF6DDC mice (Figure 1E). Together, these results
demonstrate a requirement of DC-expressed TRAF6 for induc-
tion of DC activation in response to pathogenic stimuli.
TRAF6DDC Mice Exhibit Spontaneous Small Intestine
Enteritis
DCs are important mediators of mucosal immune tolerance (Ma-
loy and Powrie, 2011; Pulendran et al., 2010). Although gut
TRAF6DDC DC subsets (characterized by CD103 and/or
CD11b expression) were found in normal proportions and
numbers, and with normal levels of membrane activation
markers (see Figures S1C and S1D available online), examina-
tion of the gut tissue of TRAF6DDC mice revealed that, by
12 weeks of age, TRAF6DDC mice begin to exhibit substantially
increased tissue length and mass specifically in the small intes-
tine (Figures 2A; Figure S1A). Histological analysis showed signs
of spontaneous enteritis, characterized by thickening of the
smooth muscle layer, hypertrophy of the intestinal crypts, blunt-
ed villi, and increased numbers of both goblet and Paneth cells
(Figure S2). There was also evidence of developing fibrosis,
Figure 2. TRAF6DDC Mice Exhibit Spontaneous Small Intestine Enteritis
(A) Lengths (n = 20) and masses (nR 5) of small intestines and colons from littermate control (WT) and TRAF6DDC (DDC) mice organized according to age at
sacrifice. Data were analyzed by one-way ANOVA with Tukey’s posttest of multiple comparisons.
(B) Trichrome staining was performed on themuscularis propria of the ileum at 27weeks of age. Collagen (blue, arrows) from Trichrome staining is amarker for gut
fibrosis. Smooth muscle layer (arrowheads) corresponds with red staining in sections.
(C) Fold increases in pro- (Acta2, Igf-1, and TGF-b) and anti- (IFN-g and IL-12) fibrotic markers in mRNA isolated from ileum of TRAF6DDC (DDC) small intestines
were compared to WT (nR 9;R 8-week-old littermate groups). Data were analyzed with two-tailed, paired Student’s t tests. **p < 0.01; ***p < 0.001. Scale bars
represent 100 mm. n.s., not significant. See also Figures S1–S4.
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ure 2B). Consistent with this observation, tissue messenger RNA
(mRNA) levels of profibrogenic factors Acta2, Igf-1, and trans-
forming growth factor-b (TGF-b) were increased, whereas antifi-
brogenic (and Th1-related) factors IL-12 and IFN-g were slightly
reduced (Figure 2C). At the same time, similar analyses revealed
TRAF6DDC colons to be unremarkable (Figure S3). These results
reveal a role for DC TRAF6 in maintaining gut homeostasis.
Spontaneous Th2 Cell Responses in the Small Intestine
of TRAF6DDC Mice
To elucidate potential cellular interactions driving small intestine
enteritis in TRAF6DDC mice, we crossed TRAF6DDC mice to a
SCID background. The small intestines of TRAF6DDC.SCID
mice appear similar to control SCID mice, even past 20 weeks
of age, and exhibit substantially reduced levels of fibrotic
markers Acta2 and Igf-1 (Figure S4), suggesting that lympho-
cytes are critical to the development of the TRAF6DDC small in-
testine phenotype. Consistent with these findings, we observed
development of lymphadenopathy of TRAF6DDC mesenteric
lymph nodes with age (Figure S1B). Analysis of serum and fecal
immunoglobulin A (IgA) titers, which are associated with B cell
activity in the mucosal lining, showed substantial increases in
TRAF6DDCmice (Figures 3A and 3B). Analysis of small intestine
lamina propria (LP) tissue gene expression from TRAF6DDC and
littermate control mice older than 8 weeks of age revealed sub-stantial increases in Th2 cell-associated factors IL-13, IL-5, and
IL-4 (Figure 3C), whereas colons from the same mice showed no
significant increases in expression and the tissue was histologi-
cally normal in appearance (data not shown.) To investigate
whether these cytokines were being produced by T cells
in situ, we performed immunofluorescent staining, which re-
vealed costaining of IL-4 and the T cell marker CD3 in
TRAF6DDC small intestinal LP (Figure 3D). Further, in
TRAF6DDC mesenteric lymph nodes we found substantially
increased numbers and frequencies of activated and/or memory
CD4+ T cells (Figure 3E), as well as more CD4+ T cells capable of
producing IL-13—but not IFN-g—upon in vitro stimulation (Fig-
ure 3F). Th2 cell-mediated intestinal phenotypes are sometimes
associated with eosinophil infiltration (Blanchard and Rothen-
berg, 2009). By staining small intestine sections with Sirius
Red, we found that TRAF6DDC mice exhibit substantially
increased eosinophil numbers (Figure 3G), potentially revealing
a parallel between the TRAF6DDC phenotype and human EGID
(eosinophilic gastrointestinal diseases; Lucendo, 2010; Master-
son et al., 2011).
Disruption of TRAF6DDC Immune Homeostasis Is Gut
Microbiota-Dependent
TRAF6 is a key transducer of TLR signaling pathways that are
tasked in part with mediating inflammatory and homeostatic in-
teractions between DCs and gut microbiota (Maloy and Powrie,Immunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc. 1213
Figure 3. Spontaneous Th2 Cell Responses in the Small Intestine of TRAF6DDC Mice
Serum (A) and fecal (B) immunoglobulin isotype levels in mice (nR 5;R 12-week-old littermate groups) were measured by ELISA.
(C) Fold increases (between TRAF6DDC mice and paired littermate control mice) in IL-13, IL-5, and IL-4 mRNA expression in small intestine (n R 8) or colon
(nR 4) tissue as measured by qPCR.
(D) Double immunofluorescent staining for CD3 and IL-4. EP, epithelial cell lining; LP, lamina propria.
(E and F) Increases in activated/memory CD4+ cells and IL-13+ cells in mesenteric lymph nodes of TRAF6DDC mice compared to littermate control mice (WT).
FACS plots gated on CD4+ T cells and show population counts and frequencies of (E) naive (CD44loCD62Lhi) versus activated/memory (CD44hiCD62Llo), and (F)
IFN-g+ and IL-13+ cells (n = 6;R 12-week-old littermate groups).
(G) Image of eosinophils (in red) stained with Sirius Red. Eosinophil infiltration is observed in small intestinal sections of TRAF6DDC and littermate control
(duodenum, 27 weeks old). FACS plots and histogram data are representative of at least three separated experiments. Data in (A) and (B) were analyzed with
two-tailed, unpaired Student’s t tests. Data in (C), (E), and (F) were analyzed with two-tailed, paired Student’s t tests. Scale bars represent 100 mm. See also
Figure S1.
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microbiota interaction with small intestine DCs is relevant to the
observed TRAF6DDC phenotype, we treated TRAF6DDC and
littermate control mice with full-spectrum antibiotics for up
to six weeks starting at 14 weeks of age. Intriguingly, we
observed that antibiotics-treated TRAF6DDC intestines now
(as compared to untreated intestines shown in Figure S1A) ex-
hibited grossly normal appearance (Figure S4B) and normal1214 Immunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc.mean length and mass (Figure 4A). Small intestine mRNA levels
of both profibrotic and Th2 cell-associated genes were substan-
tially reduced under antibiotic treatment (as compared to un-
treated) conditions (Figure 4B). Further, antibiotics-treated
mice exhibited substantial reductions in both the frequency
and number of IL-13-producing CD4+ T cells isolated from the
small intestinal LP (Figure 4C). Finally, histological sections of
TRAF6DDC small intestine tissue from antibiotics-treated mice
Figure 4. Disruption of TRAF6DDC Immune
Homeostasis Is Gut Microbiota Dependent
(A) Lengths and masses (nR 7 per group) of small
intestines from 8- to 20-week-old littermate-
matched control (WT) and TRAF6DDC (DDC) mice
provided untreated or antibiotics-treated (Abx)
water for the final 6 weeks. ***p < 0.001.
(B) Fibrosis markers (Acta2 and Igf-1) and Th2 cell
cytokines (IL-13, IL-5, and IL-4) mRNA expression
levels in the ileum region of small intestines from
mice treated with full-spectrum antibiotics (Abx).
Histograms (mean ± SD) are representative of
three independent experiments.
(C) Intracellular staining for IFN-g, IL-13, and
Foxp3 in mesenteric lymph nodes of antibiotics-
treated (Abx) or untreated mice. FACS plots were
gated on CD4+ T cells and cell counts of IL-13-
producing cells are shown in the histogram. FACS
plots are representative of three independent ex-
periments. The histograms represent means ± SD.
(D) Sirius Red staining of the duodenum region of
small intestine from antibiotics-treated (Abx) mice.
Antibiotic water containing 1 g/L Ampicillin, 1 g/L
Neomycin, 0.5 g/L Vancomycin, and 1 g/L
Metronidazole was provided ad libitum in water to
14-week-old mice for 6 weeks. Data in (A), (B), and
(C) were analyzed by one-way ANOVA with Tu-
key’s posttest of multiple comparisons. *p < 0.05;
**p < 0.01. Scale bars represent 100 mm. n.s., not
significant. See also Figures S4.
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suggesting an absence of eosinophil infiltration (Figure 4D).
Therefore, aberrant immune homeostasis related to TRAF6-
deficient gut DCs is triggered only when commensal microbiota
are present.Immunity 38, 1211–122MyD88DDC Mice Do Not
Phenocopy Aberrant Immune
Homeostasis of TRAF6DDC Mice
TRAF6 and MyD88 carry out critical
nonredundant roles as mediators of TLR
signaling (Inoue et al., 2007; Takeda and
Akira, 2004), with MyD88-IRAK com-
plexes leading to activation of TRAF6
and subsequently NF-kB and MAPKs.
DC-specific MyD88 conditional knockout
mice (MyD88DDC) utilizing the same
CD11c-Cre system that we have em-
ployed for TRAF6DDC have previously
been studied, and although MyD88DDC
exhibit defects in TLR-mediated activa-
tion and induction of Th1-associated im-
munity (consistent with our observations
of TRAF6DDCmice), no aberrant immune
homeostasis in the gut is reported (Hou
et al., 2008). Given the significance of
the MyD88-TRAF6 signaling juncture
to DC biology (especially in the context
of TLR signaling), together with our ob-
servations that TRAF6DDC phenotypes
are substantially influenced by TLRligand-producing gut microbiota, we decided to reexamine
MyD88DDC mice side by side with TRAF6DDC mice to deter-
mine whether previous analyses may have yielded different re-
sults based on housing-specific factors (e.g., quantitatively
and/or qualitatively distinct intestinal microbiota). Interestingly,2, June 27, 2013 ª2013 Elsevier Inc. 1215
Figure 5. MyD88DDC Mice Do Not Phenocopy Aberrant Immune Homeostasis of TRAF6DDC Mice
(A) Length of gut was measured in MyD88DDC mice (88DDC) and littermate controls (WT).
(B) Relative mRNA levels in 20-week-old ileum of MyD88DDC mice and littermate controls (WT). The histograms (mean ± SD) are representative of three in-
dependent experiments.
(C) Sirius Red staining was performed in the ileum section of small intestine from 20-week-old mice.
(D) FACS plots gated on CD4+ T cells showing Intracellular staining for Th1 and Th2 cell cytokines (IFN-g and IL-13, respectively) in mesenteric lymph nodes from
20-week-old mice and cytokine-producing cell counts. FACS plots and histogram data are representative of three independent experiments. Scale bars
represent 100 mm. See also Figure S5.
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ferences in small intestine length versus littermate controls (Fig-
ure 5A), no increases in profibrotic or Th2 cell-associated mRNA
levels in small intestine tissue samples (Figure 5B), and no
apparent eosinophil infiltration of the small intestine (Figure 5C).
Further, CD4+ T cells isolated from small intestinal LP exhibited
frequencies and numbers of IL-13-producing cells no different
from littermate controls, and much lower than similar cells iso-
lated at the same time from TRAF6DDC mice (Figure 5D), sug-
gesting the existence of a MyD88-independent component to
the TRAF6DDC small intestine phenotype. We further consid-
ered the possibility that genetic manipulation of DC signaling
components may exert indirect external population effects on
the surrounding commensal microbiota. However, profiling of
fecal bacterial communities of control, TRAF6DDC, and
MyD88DDC mice by deep sequencing showed that the most
abundant types of bacterial taxa were common among commu-
nities of all three genotypes, and their proportions were not
significantly different (Figure S5), implying that differences be-
tween TRAF6DDC and MyD88DDC phenotypes are not likely
the result of the presence of altered bacteria-derived stimuli in
TRAF6DDC intestines.1216 Immunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc.Microbiota-Dependent Reduction in TRAF6DDC Small
Intestine Treg Cells
One mechanism by which mucosal DCs maintain tolerance
is through the induction and maintenance of iTreg cells (Pulen-
dran et al., 2010; Rescigno, 2010), regulatory T cells that acquire
their suppressive phenotype in peripheral tissues rather than
in the thymus. We analyzed TRAF6DDC intestinal LP and
found decreased numbers and frequencies of Treg cells (by
Foxp3 expression) in mice as young as 6 weeks of age, and
importantly, these defects were found in the small intestine,
but not the colon (Figure 6A). Consistent with their lack of
spontaneous enteritis, MyD88DDC mice of similar ages and
genders to analyzed TRAF6DDC mice were found to have
normal Treg cell populations (Figure S6). To determine whether
the TRAF6DDC Treg cell defect is also dependent on gut
microbiota, we again treated mice with full-spectrum antibiotics,
but this time started at 4 weeks of age to account for the early
presentation of the Treg cell defect. Interestingly, we found
that 2 weeks of treatment was sufficient to partially restore the
frequency (within the total CD4+ T cell population) and
completely restore the number of Treg cells located in the
TRAF6DDC small intestine (Figure 6B). Therefore, defective
Figure 6. Microbiota-Dependent Reduction in TRAF6DDC Small Intestine Treg Cells
(A) FACS plots gated on CD4+ T cells show intracellular staining for small intestine or colon lamina propria lymphocytes from 6- to 8-week-old TRAF6DDC and
littermate control mice and Foxp3+ as a percentage of CD4+ and cell counts. Data were analyzed with two-tailed, paired Student’s t test.
(B) Intracellular staining for Foxp3 in small intestinal lamina propria of antibiotics-treated (Abx) or untreated mice. FACS plots were gated on CD4+ T cells. Water
containing 1 g/L Ampicillin, 1 g/L Neomycin, 0.5 g/L Vancomycin, 1 g/LMetronidazole was provided to 4-week-old mice for 2 weeks. The histograms (mean ± SD)
were analyzed by one-way ANOVA with Tukey’s posttest of multiple comparisons. FACS plots in (A) and (B) are representative of at least three separate ex-
periments. **p < 0.01; ***p < 0.001. N.S., not significant. See also Figures S6 and S7.
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ence of microbiota.
Defective DC-Expressed IL-2 and Rescue of Treg Cells
via Exogenous IL-2 in TRAF6DDC Mice
To uncover potential mechanistic bases for diminished Treg cell
numbers in TRAF6DDC LP, we investigated the potential roles of
cell surfacemarkers and other proteins reportedly involved in the
induction of intestinal iTreg cells by DCs. Numerous factors,
including Aldh1a2, TGF-b, integrin-av, and integrin-b8 showed
no apparent difference between control and TRAF6DDC (Fig-
ure S7). This process led us to focus on IL-2, which is not only
critical to Treg cell development and maintenance (Malek and
Castro, 2010), but which has also been shown to be expressed
by DCs (Granucci et al., 2001), and its expression by DCs might
play a role in Treg cell maintenance (Kulhankova et al., 2012;
Sgouroudis et al., 2011). We have also found that blocking IL-2
or use of IL-2-deficient DCs results in diminished Treg cell con-
version (Figure S8). Interestingly, we examined IL-2 expression
in control, MyD88DDC, and TRAF6DDC LP DCs and found that
although IL-2 mRNA levels in both control and MyD88DDC sam-
ples were similar, levels in TRAF6DDC LP DCs were dramatically
reduced (Figure 7A). TRAF6DDC LP DCs similarly exhibited
decreased IL-2 protein elaboration during brief ex vivo culture
(Figure 7B). Next, we showed that although DCs from
TRAF6DDC mice are defective inducers of Foxp3 in in vitro
Treg cell conversion assays, provision of IL-2 to these cultures
had a corrective effect on this defect (Figure 7C). Finally, we simi-
larly showed that defective in vivo model antigen-induced Treg
cell conversion of adoptively-transferred TCR transgenic
T cells into TRAF6DDC recipients could be restored to the higher
levels observed in MyD88DDC recipients (which are similar to
those observed for control recipients) through provision ofbioactive IL-2–aIL-2 complexes (Figure 7D). Together, these
findings suggest that the decreased capacity of DCs from
TRAF6DDCmice to induce the Treg cell phenotype can be over-
come by provision of the pro-Treg cell cytokine IL-2 and raises
the possibility that DC-expressed IL-2 is required for normal
Treg cell homeostasis in the gut.
Defective TRAF6DDC iTreg Cell Induction Is Linked to
Aberrant Th2 Cell Development
Decreased Treg cell numbers in the small intestine raised the
possibility that Treg cell maintenance and/or iTreg cell induction
are defective in TRAF6DDCmice. To address the first possibility,
we sorted GFP-expressing peripheral Treg cells from transgenic
mice expressing GFP under the control of the Foxp3 promoter
(Fontenot et al., 2005) and transferred these cells into control
or TRAF6DDC recipient mice. After 1 week, the populations
of transferred cells were identified by GFP expression and
enumerated. Whereas endogenous levels of TRAF6DDC Treg
populations were decreased (as expected: Figure 7E, left), the
transferred populations appeared at normal levels (Figure 7E,
middle and right.) Therefore, to address the alternative possibility
of defective iTreg cell induction, we adoptively transferred sorted
naive (CD44loCD62LhiCD25) Thy1.1 congenic OVA-specific
OT-II CD4+ T cells into TRAF6DDC or littermate control mice fol-
lowed by 5 days of oral administration of OVA peptide. By using
congenic markers, transferred cells were identified after 1 week
and Foxp3 staining revealed that TRAF6DDC recipient mice
exhibit substantially reduced capability to induce Treg cells in
response to model oral antigen (Figure 7F).
These findings raised the possibility that reduced Treg cell
function in TRAF6DDC mice may be linked to spontaneous in-
duction of intestinal Th2 cell immunity. To restore robust Treg
cell function experimentally, we crossed Foxp3-GFP mice withImmunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc. 1217
Figure 7. Treg Homeostasis and Gut Immune Tolerance in
TRAF6DDC Mice Is Linked to Regulation of DC-Expressed IL-2
(A) IL-2 mRNA expression levels in MACS-purified lamina propria DCs from
WT, MyD88DDC (88DDC), and TRAF6DDC (T6DDC) mice.
(B) ELISA of IL-2 proteins levels elaborated by WT and TRAF6DDC (DDC)
lamina propria DCs cultured for 12 hr with 50 ng/mL PMA and 500 ng/mL
ionomycin. ***p < 0.001.
(C) Counts of Foxp3+ cells converted from naive-effector OT-II CD4+ T cells
after 4 days culture with purified lamina propria DCs (5 3 104 T cells and 5 3
103 DCs) from WT or TRAF6DDC (T6DDC) (1 mM OVA 323–332 and 1 ng/ml
TGF-b in all cultures) in the presence (IL-2+) or absence (IL-2) of 10 U/mL
recombinant IL-2.
(D) FACS plots and histograms show the frequencies of Foxp3+ OT-II donor
cells in mesenteric lymph nodes after 5 days of OVA feeding. MyD88DDC
Immunity
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1218 Immunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc.transgenic mice expressing a constitutively active form of the
pro-Treg cell transcription factor STAT5b (Burchill et al., 2003)
(Foxp3-GFP.STAT5bCA) and then adoptively transferred sorted
Foxp3-GFP+ Treg cells from thosemice into either TRAF6DDCor
littermate control recipients. Foxp3-GFP.STAT5bCA Treg cells
were used because they were obtainable in large numbers,
and, we reasoned, would be more stable as a population
(capable of reliably providing Treg cell activity) once transferred.
This was important because the TRAF6DDC gut phenotype
developed over an extended time period. Four weeks after trans-
fer, we observed that TRAF6DDC mice that had received
STAT5bCA Treg cells had partially restored Treg cell numbers,
and more importantly, exhibited reduced frequencies and
numbers of small intestinal LP Th2 cell cells and cytokine expres-
sion (Figures 7G and 7H). These findings suggested a direct link
between Treg cell function and spontaneous development of
aberrant gut immune responses in TRAF6DDC mice.
DISCUSSION
DCs are important for both activation of inflammatory T cell
immune responses and maintenance of T cell tolerance. By
generating mice that specifically lack DC-expressed TRAF6,
we have been able to characterize a new role for TRAF6 in direct-
ing DC maintenance of intestinal immune tolerance. Although
TRAF6DDC mice were found to exhibit some predicted (given
our previous work with Traf6/ DCs) phenotypes, such as
defective induction of TLR-mediated peripheral Th1 cell-associ-
ated responses, we were surprised to find that these mice also
exhibit defective intestinal iTreg cell induction and subsequent
spontaneous Th2 cell-associated disruption of immune homeo-
stasis. Intriguingly, these TRAF6DDC phenotypes were found
to be dependent on the presence of gut microbiota, whereas
mice lacking MyD88, the signaling protein that links TLRs to
TRAF6, in DCs (MyD88DDC) did not exhibit any signs of disease
onset or decreased Treg cell numbers. Furthermore, we have
shown that LP DCs harvested from TRAF6DDC mice exhibit
dramatically reduced levels of IL-2 mRNA and that IL-2 provision(88DDC) and TRAF6DDC (T6DDC) mice were used as recipients. IL-2-mAb
complex (IL-2 complex) was injected as indicated for the first 3 days of OVA-
feeding.
(E) FACS sorted Foxp3-GFP+ cells (0.5 3 106) were transferred to WT or
TRAF6DDC recipients. Cells were isolated and analyzed from small intestinal
lamina propria 7 days after transfer. The histograms show the Foxp3-GFP+
(donor) cells as a ratio of total Foxp3+ cells and counts of Foxp3-GFP+ cells in
the gut (n = 3).
(F) Intracellular staining and cell counts of converted donor OT-II cells recov-
ered from mesenteric lymph nodes of mice fed OVA protein for 5 days. FACS
plots depict gated CD45.1+ (donor marker) and CD4+ T cells.
(G and H) STAT5bCA transgenic Foxp3-GFP+ regulatory T cells (STAT5tg Treg
cell) were transferred to TRAF6DDC and littermate control recipients. (G) FACS
plots showing Intracellular staining for Th1 and Th2 cell cytokines (IFN-g and
IL-13, respectively) 4 weeks after transfer. The percentages and counts for
Foxp3+ or IL-13+ fromCD4+ T cells inmesenteric lymph nodes, and (H) Th2 cell
cytokine (IL-4) mRNA expression level from ileum of both adoptively trans-
ferred and no transfer control groups. FACS plots and graphs are represen-
tative of at least three separate experiments. The histograms are represented
as mean ± SD. Data in (C), (D), and (G) were analyzed by one-way ANOVA with
Tukey’s posttest of multiple comparisons. *p < 0.05; **p < 0.01; ***p < 0.001.
n.s., not significant. See also Figure S8.
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in multiple contexts. These findings represent a potentially
significant link between TRAF6 signaling pathways and the pro-
duction of cytokines functionally relevant to the maintenance of
immune tolerance. Further, in light of recent work by Kulhankova
et al. regarding juxtacrine relationships of IL-2 with DCs and Treg
cells (Kulhankova et al., 2012), it will be especially interesting to
further investigate the potential role of TRAF6-dependent
signaling in this relationship. It is also important to point out
that identification of a potential role for DC-expressed IL-2 in
TRAF6DDC Treg cell homeostasis does not exclude the possibil-
ity that other Treg cell-associated cytokines, such as IL-10, are
also relevant. However, at this time, we have not identified any
irregular expression patterns of such factors in DCs isolated
from TRAF6DDC mice.
Decoding the complex signaling networks that govern the re-
lationships between DC-mediated tolerance and immunity, and
being able to do so in a physiologic setting (and avoiding the dif-
ficulties associated with studying DCs ex vivo), represented sig-
nificant motivations for generating and studying TRAF6DDC
mice. It is instructive to consider our observations of the in vivo
relevance of DC-expressed TRAF6 in the context of some
TRAF6-associated signaling factors that have been similarly
analyzed. To begin with, because of the divergent phenotypes
described above in TRAF6DDC and MyD88DDC mice in the
presence of TLR ligand-bearing microbiota, we infer: (1) that
TLRs activate a MyD88-independent, TRAF6-dependent
pathway that serves to promote a tolerogenic phenotype in
DCs (this pathway could involve the TLR adaptor TRIF [Takeda
and Akira, 2004] and/or the NOD2-RIP2 signaling complex
[Brand, 2009; Fritz et al., 2011]); (2) that microbiota act directly
or indirectly on DCs through pattern-recognition receptor
(PRR)-independent pathways (such as extracellular ATP, which
has been shown to act through P2X and P2Y receptors to modu-
late regulation of immune tolerance by DCs [Atarashi et al., 2008;
Idzko et al., 2007]); or (3) that TLRs stimulate production of fac-
tors by non-DCs (e.g., epithelial, Paneth, goblet, other lymphoid
or myeloid cells) that then act on DCs through known TRAF6-
dependent, MyD88-independent pathways (e.g., TGF-b,
CD40L, RANKL, IL-25 [Chang and Dong, 2011; Landstro¨m,
2010; Walsh et al., 2006]).
TAK1 is the primary kinase activated by TRAF6, but TAK1DDC
mice that lack TAK1 in the DC compartment are not reported to
develop a similar gut phenotype (Wang et al., 2007). However,
TAK1DDC mice do exhibit a Treg cell defect. The reason
TRAF6DDCmice exhibit loss of gut immune tolerance in addition
to the similar Treg cell phenotype is likely because DCs in
TRAF6DDC mice retain sufficient TAK1 activity to avoid the
massive survival defect of TAK1DDC DCs that would preclude
the development of Th2 cells. Unlike TAK1, the ubiquitin-editing
molecule A20 is a negative regulator of TRAF6-mediated
signaling (Shembade et al., 2010). Recent reports describe
mice lacking DC-expressed A20 (A20DDC) as developing spon-
taneous Th1-associated peripheral autoimmunity (Hammer
et al., 2011; Kool et al., 2011), and one study identifies the DC-
intrinsic pathway responsible for T cell expansion and inflamma-
tory cytokine elaboration as being MyD88-dependent (and
therefore, possibly TRAF6-dependent). Consistent with an in-
verted phenotype (in relation to TRAF6DDC), Treg cell numbersin A20DDC mice are reported to be normal (Hammer et al.,
2011) or even increased (Kool et al., 2011).
TRAF6 is also involved in TGFbR signaling (Landstro¨m, 2010),
primarily through activation of TAK1 (Sorrentino et al., 2008).
Recent reports indicate that complete ablation of TGFbR1-
ALK-5 signaling in DCs results in loss of Langerhans cells (Kel
et al., 2010), while DC-specific deletion of avb8 integrin, which
activates the precursor form of TGF-b, reveals a phenotype
bearing some similarity to TRAF6DDC, including age-related
development of inflammatory bowel disease associated with
decreased gut Treg cells (though in the colon rather than the
small intestine) (Travis et al., 2007). These findings may imply a
role for the TRAF6-specific component of TGFbR signaling in
DCs for maintaining mucosal homeostasis.
One of themost curious features of the TRAF6DDC gut pheno-
type is the exacerbating role that gut microbiota play. The fact
that depletion of commensal bacteria increased small intestinal
LP Treg cells seems to contrast recent findings that commensal
bacteria boost gut Treg cell numbers (Atarashi et al., 2011),
though these differences may be explained by the fact that these
studies were performed for Treg cells in the colon, where
commensal-related stimuli are substantially higher than and
qualitatively different from the small intestine (Santaolalla et al.,
2011; Swiatczak and Rescigno, 2012). Additionally, it is possible
that TRAF6 expression in DCs differentially impacts the distribu-
tion between the small and large intestines of DC subsets. Spe-
cifically, the major subset of mucosal DCs responsible for
inducing iTreg cells, the vitamin A-metabolizing CD103+ subset,
is present at higher numbers in the small intestine (Agace and
Persson, 2012) andmight bemore dependent on TRAF6-depen-
dent signals. The primary defect in TRAF6DDCmicemight derive
first from failure to sufficiently induce small intestine iTreg cells,
though thus far we have found TRAF6DDC CD103+ DCs present
in normal numbers expressing normal levels of Retinaldehyde
dehydrogenases RALDH1 and RALDH2 (data not shown).
It should also be noted that although we have not identified
any phenotypic differences in small intestinal DCs in TRAF6DDC
mice that might explain why these mice exhibit an iTreg cell
defect and Th2 cell-associated autoimmunity, there are certain
caveats attached to DC analysis in the gut. First, regarding
enumeration, preps are relatively complex and can lead to signif-
icant variability between labs and even within labs (Rescigno,
2011). This difficulty must be given special consideration in the
case of TRAF6DDC because the small intestine tissues become
enlarged and fibrotic with disease onset, thereby altering, with
respect to control mice, expectations about DC prep efficiency.
Second, beyond CD103 and CD11b, there are numerous other
markers, including many chemokine receptors (e.g., CX3CR1
and CCR7, as well as CD70), which identify specialized DC sub-
sets. It is difficult to determine, therefore, whether relevant de-
fects in TRAF6DDC DCs exist in specific subsets that constitute
a minority population. Alternatively, it is possible that disease in
TRAF6DDC mice is mediated by a DC subset not yet character-
ized. Clearly, additional effort will be required to determine the
specific nature of the relevant cellular and signaling defect(s) in
TRAF6DDC mice.
Overall, the TRAF6DDC mouse dramatically identifies a novel
example of a DC signaling mediator that is critical for activation
of the immune response in one anatomic and stimulatory contextImmunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc. 1219
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believe that this unusual status makes TRAF6DDC a valuable
model for further elucidating, in a physiologic setting, the mech-




TRAF6DDC and MyD88DDC mice were generated by crossing mice carrying
floxed alleles of Traf6 (King et al., 2006) or MyD88 (Hou et al., 2008) with
CD11c Cre transgenic mice (Caton et al., 2007). All mice were backcrossed
to B6 background more than ten generations. OT-II transgenic (B6.Cg-Tg
[TcraTcrb]425Cbn/J), SCID (B6.CB17-Prkdcscid/SzJ), and congenic (CD45.1,
B6.SJL-Ptprca Pepcb/BoyJ) mice were purchased from Jackson laboratories.
STAT5b-CA transgenic mice (Burchill et al., 2003), Foxp3-GFP mice (Fontenot
et al., 2005), and IL-2-GFP knock-in mice (McKarns and Schwartz, 2008; Nar-
amura et al., 1998) were kind gifts from M.A. Farrar (University of Minnesota),
A.Y. Rudensky (Sloan Kettering), and Ronald Schwartz (NIH), respectively. All
experimental pairs of mice were cohoused. Mouse care and experimental pro-
cedures were performed in accordance with protocols from Institutional Ani-
mal Care and Use Committees of the University of Pennsylvania.
Buffers and Media
Sort buffer containing 2% FBS and 0.7 mM EDTA was used to prepare, stain,
and wash isolated cells. Complete RPMI-1640 medium containing 10% FBS,
10 U/ml Penicillin, 10 mg/ml Streptomycin, 2 mM L-glutamin (Invitrogen), and
50 mM b-mercapotethanol (Sigma) was used for cell culture. Gey’s solution
composed of 155 mM NH4Cl (Sigma) and 10 mM KHCO3 (Sigma) was used
for red blood cell lysis.
Quantitative PCR
Tissues or purified cells were homogenized in TRIzol (Invitrogen) after freezing
in liquid nitrogen. cDNAs were established by using Superscript III (invitrogen)
and random hexamer (QIAGEN). TaqMan gene probes were used with
TaqMan Universal PCR Master Mix (Applied Biosystems) and run on 7300
Realtime PCR System (Applied Biosystems): 2 min at 50C, 10 min at 95C,
50 cycles of 15 s 95C, 1 min at 60C, and signals were detected during an-
nealing step (60C). Relative mRNA expression levels of all samples were
normalized to 18S mRNA. The TaqMan gene probes (Applied Biosystems)
used: Acta2 (Mm01546113_m1), Igf1 (Mm00439560_m1), Tgfb1
(Mm00441724_m1), Ifng (Mm01168134_m1), Il2 (Mm00434256_m1), Il12b
(Mm99999067_m1), Il13 (Mm99999190_m1), Il5 (Mm00439646_m1), Il4
(Mm00445259_m1), and 18S ribosomal RNA (Hs99999901_s1).
ELISA
For serum immunoglobulin levels, serum was diluted to 1:10,000–100,000 and
immunoglobulin isotype levels measured by eBioscience ELISA kit. For fecal
IgA, feces were weighed and homogenized in 10-fold (v/w) PBS containing
0.01% NaN3. Supernatants were diluted 1:1000 after centrifuging at 4
C and
10,000 rpm for 5 min. IgA level was determined by eBioscience ELISA kit.
For IL-2 detection, 3 3 104 DCs (purified from small intestine LP with anti-
CD11c MACS beads, Miltenyi Biotech) per triplicate well were stimulated
with 500 ng/ml ionomycin and 50 ng/ml PMA (Sigma) for 12 hr. Supernatant
concentration of IL-2 was determined with an ELISA kit according to manufac-
turer instructions (eBioscience). Purified a-IL-2 (JES6-aA12) was used for
capture and biotin-conjugated a-IL-2 (JES6-5H4) for detection.
Cell Isolation
Single cells were isolated from spleen and mesenteric lymph nodes by me-
chanical disruption on 70 mmcell strainers (BD). For small intestinal LP lympho-
cyte (LPL) isolation, epithelial cells were removed by incubation in stripping
RPMI-1640 medium containing 10% FBS, 5 mM EDTA, 1 mM DTT, and
20mMHEPES at 37C for 15min in shaker. The remaining pieces wereminced
and incubated in serum-free RPMI-1640 medium containing 52 U/ml Liverase
TM (Roche), 50 mg/ml DNaseI (Sigma), and 20 mM HEPES at 37C for 15 min
while shaking. For T cell enrichment, LPLs were separated with Percoll1220 Immunity 38, 1211–1222, June 27, 2013 ª2013 Elsevier Inc.gradient (GE Healthcare). Cells were collected at the interface between 40%
and 70% after centrifuging at 2,500 rpm at room temperature for 20 min
with no brake. For DC enrichment, 145 mg/ml Histodenz (Sigma) dissolved in
sort buffer was used at 2,500 rpm, 4C for 15 min with no brake. For gene
expression assay, LP dendritic cells (LpDCs) were isolated by MACS purifica-
tion (Miltenyi Biotec) by using magnetic bead-conjugated anti-CD11c
antibody.
Flow Cytometry
We used 1 3 106 cells for surface staining in FACS buffer containing a-CD16/
32 (2.4G2) and LIVE/DEAD dye (Invitrogen) with combinations of fluoro-
chrome-conjugated antibodies including CD44 (IM7), CD62L (MEL-14),
CD25 (PC61.5), CD8 (53-6.7), CD4 (RM4-5), I-Ab (AF6-120.1), CD45.1 (A20),
CD45.2 (104), CD11b (M1/70), CD11c (HL3), B220 (RA3-6B2), CD90.2 (53-
2.1), and CD103 (2E7). For intracellular staining, cells were stimulated in
round-bottom 96-well plates with complete RPMI1640 medium containing
500 ng/ml Ionomycin and 5 ng/ml PMA (Sigma) in the presence of Brefeldin
A (BD) for the last 3 hr. After surface staining, the cells were fixed and permea-
bilized with fixation/permeabilization reagent (eBioscience) and stained with
intracellular protein-specific antibodies reconizing IL-12p40/p70 (C15.6), IL-
13 (eBio13A), IFN-g (XMG1.2), and Foxp3 (FJK-16 s). All stained samples
were analyzed on an LSRII flow cytometer (BD) and the raw data were calcu-
lated and visualizedwith FlowJo software (Tree Star). All of the antibodies were
purchased from BD or eBioscience.
LCMV infection
We administered 2 3 105 PFU of LCMV-Armstrong to mice by intraperitoneal
injection. We stimulated 1 3 106 isolated cells from spleen of the mice 7 days
after infection by PMA and ionomycin with Brefeldin A treatment for the last
3 hr. After surface marker staining with CD4 and CD44 antibodies, the cells
were fixed and permeabilzed by BD Cytofix/Cytoperm Fixation and Permeabi-
lization Solution kit for intracellular staining with IFN-g antibody.
Histology and Immunofluorescence
Intestinal specimens were cut longitudinally and formed into inside-out Swiss
rolls. Paraffin-embedded sections were performed after fixation in 10%
Formalin solution (Fisher Diagnostics). Trichrome staining and Sirius Red stain-
ing were performed by the Penn Center for Molecular Studies in Digestive and
Liver Diseases. Briefly, for Sirius Red staining, hematocylin was used for
nucleus staining, and Sirius Red solution was used for eosinophil staining. Tri-
chrome staining was used for staining muscle, cytoplasm, and collagen. For
immunofluorescence staining, antigen retrieval of paraffin slides was per-
formed in boiled 0.01 M sodium citrate buffer (pH 6.0) followed by deparaffini-
zation and rehydration. Primary staining with a-CD3 (ab5690, Abcam) and
a-IL-4 (BVD4-1D11, Abcam) was performed overnight at 4C after specimens
were blocked with 5% host serum of secondary antibodies. Specimens were
examined by using a fluorescence microscope (Olympus) after staining with
fluorochrome-conjugated secondary antibodies including Alexa Fluor 488
a-rat IgG (A21208, Invitrogen) and Alexa Fluor 568 a-rabbit IgG (A10042,
Invitrogen) and then mounting.
Antibiotic Treatment
Full-spectrum antibiotic treatment was supplied for 2–6 weeks in drinking wa-
ter containing ampicillin (1 g/L, Cellgro), vancomycin (0.5 g/L, Calbiochem),
neomycin sulfate (1 g/L, Calbiochem), and metronidazole (1 g/L, Santa Cruz
Biotechnology). The antibiotic solution was refreshed every 4 days.
In Vitro Treg Cell Conversion
We mixed 53 104 naive CD4 OT-II cells isolated by FACS Aria cell sorter (BD)
and 5 3 103 LpDCs a 96 well round-bottom plate with 1 mM OVA 323–332
and 1 ng/ml TGF-b. After 4 days, cells were counted, fixed and permeabilized
with fixation/permeabilization reagent (eBioscience), and stained for
surface markers and Foxp3. Stained cells were analyzed on an LSRII flow
cytometer (BD).
IL-2-mAb Complex Treatment
Naive congenic OT-II (CD45.1+CD4+CD62LhiCD44loCD25) cells isolated with
a FACS Aria cell sorter (BD) were transferred intravenously into TRAF6DDC or
Immunity
TRAF6 in DCs Controls Intestinal Immune Tolerancegender and age-matched control recipients (1 3 106 donor cells per mouse).
We orally provided 5 mg OVA protein (Sigma) dissolved in PBS to recipients
for 5 consecutive days starting 24 hr after transfer. IL-2-mAb complex was pre-
pared in PBSmixedwith 1 mg IL-2 (R&D) and 5 mg anti-IL-2 mAb (clone JES6-1;
gift from Charles D. Surh [Webster et al., 2009]). The complex was injected
intraperitoneally on a daily basis during the first 4 days of OVA treatment.
The donor cells were harvested and analyzed from mesenteric lymph nodes
on day 6.
In Vivo Treg cell Conversion
Congenic OT-II naive (CD45.1+CD4+CD62LhiCD44loCD25) cells isolated with
a FACS Aria cell sorter (BD) were transferred intravenously into TRAF6DDC or
gender-matched littermate control recipients (13 106 donor cells per mouse).
We orally provided 5mgOVA protein (Sigma) dissolved in PBS to recipients for
5 days in a row from the following day of transfer. Cells were harvested from
mesenteric lymph nodes and analyzed on day 6.
Adoptive Transfer of Treg Cells
Single cells were isolated from spleen and lymph nodes of Foxp3-GFPmice or
STAT5b transgenic Foxp3-GFP mice. CD4, GFP double-positive cells were
collected with a FACS Aria cell sorter (BD), and 0.5–3 106 cells injected intra-
venously to each recipient. Mice were sacrificed and analyzed after 4 weeks.
Statistics
Prism software (GraphPad) and either an unpaired or paired Student’s t test
were used for data analysis. p values less than 0.05 were considered
significant.
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